Vimarsana
Biggest News Aggregation in the World

Page 9 - Caredx Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Caredx Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Caredx Inc Today - Breaking & Trending Today

CareDx Reports Third Quarter 2023 Results - Vimarsana News

CareDx Reports Third Quarter 2023 Results

CareDx, Inc. — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and...

CareDx: Q3 Earnings Snapshot - Vimarsana News

CareDx: Q3 Earnings Snapshot

BRISBANE, Calif. (AP) — BRISBANE, Calif. (AP) — CareDx Inc. (CDNA) on Wednesday reported a loss of $23.5 million in its third quarter.

Related Topics:
United StatesCaredx Inc
Global HLA Typing Market Size is to grow from USD 1.1 billion in 2023 to USD 2.1 billion by 2033, at a CAGR of 6.7% - Vimarsana News

Global HLA Typing Market Size is to grow from USD 1.1 billion in 2023 to USD 2.1 billion by 2033, at a CAGR of 6.7%

/PRNewswire/ -- The global HLA typing market is estimated to secure a valuation of US$ 1.1 billion in 2023 and is estimated to rise to US$ 2.1 billion by 2033....

NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA -November 03, 2023 at 10:51 pm EDT - Vimarsana News

NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA -November 03, 2023 at 10:51 pm EDT

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Natera, Inc. . On...

NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights - Vimarsana News

NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights

--Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023-- --Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438--...